Esperion Therapeutics (ESPR) Misses Q1 EPS by 8c

Esperion Therapeutics (NASDAQ: ESPR) reported Q1 EPS of ($0.56), $0.08 worse than the analyst estimate of ($0.48).

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• BofA maintains underperform ratings on six BDC stocks
• Bernstein remains bullish on SpaceX but sees challenges in telecom ambitions